Dorota Haznar-Garbacz

Dr. Dorota Haznar-Garbacz

orcid

Research Focus & Metrics

Representative Publications

View All Publications
1 May 2015 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
DSD. Schönherr
D. Schönherr
UWU. Wollatz
U. Wollatz
DHDorota Haznar-Garbacz
Dorota Haznar-Garbacz
UHU. Hanke
U. Hanke
KBK.J. Box
K.J. Box
Werner WeitschiesWerner Weitschies
Werner Weitschies

1 October 2021 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Open access
DHDagmara Hoc
Dagmara Hoc
DHDorota Haznar-Garbacz
Dorota Haznar-Garbacz
Foams are multiphase systems found throughout nature. We meet them equally often in our everyday life, starting with the foam in the morning espresso, where the foam should constitute 10% of the drink or in a glass of beer and ending with the evening bath with foam. These multiphase systems consist mainly of gas, which is separated by liquid or solid lamellae. The lamellae have a very large surface area and a small thickness, which results in their low stability. The foams in pharmaceutics are known for a long time as protective or therapeutic preparations for topical use. However, the physicochemical structure of both solid and liquid foams offers multiple fields of application in the modern therapy. For instance, owing to the unique structure, foams can be also used for parenteral use in the form of implants serving as a drug carrier and at the same time, a scaffold for regenerating the tissue. Foams can also be used orally in the form of controlled drug delivery systems that are potentially useful for sustained or targeted drug delivery. The article describes the unique advantages and features of foams that make them useful in modern pharmacotherapy.

7 July 2015 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
EKEwa Kaminska
Ewa Kaminska
MTM. Tarnacka
M. Tarnacka
PWP. Wlodarczyk
P. Wlodarczyk
KJKarolina Jurkiewicz
Karolina Jurkiewicz
KKK. Kolodziejczyk
K. Kolodziejczyk
MPM. Paluch
M. Paluch

1 April 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Piotr KulinowskiPiotr Kulinowski
Piotr Kulinowski
KWKrzysztof Woyna-Orlewicz
Krzysztof Woyna-Orlewicz
GRGerd-Martin Rappen
Gerd-Martin Rappen
DHDorota Haznar-Garbacz
Dorota Haznar-Garbacz
WWWładysław Węglarz
Władysław Węglarz
PDPrzemysław P. Dorożyński
Przemysław P. Dorożyński

1 February 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Piotr KulinowskiPiotr Kulinowski
Piotr Kulinowski
KWKrzysztof Woyna-Orlewicz
Krzysztof Woyna-Orlewicz
JOJadwiga Obrał
Jadwiga Obrał
GRGerd-Martin Rappen
Gerd-Martin Rappen
DHDorota Haznar-Garbacz
Dorota Haznar-Garbacz
Przemysław DorożyńskiPrzemysław Dorożyński
Przemysław Dorożyński

28 May 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Daniel ZakowieckiDaniel Zakowiecki
Daniel Zakowiecki
MFMaja Frankiewicz
Maja Frankiewicz
Tobias HessTobias Hess
Tobias Hess
Krzysztof CalKrzysztof Cal
Krzysztof Cal
MGMaciej Gajda
Maciej Gajda
DHDorota Haznar-Garbacz
Dorota Haznar-Garbacz
Novel calcium phosphate-based starter pellets were used to develop a biphasic-release multiple-unit pellet system (MUPS) with diclofenac sodium as a model drug in the form of hard gelatin capsules. For comparative purposes, corresponding formulations based on the inert cores made of microcrystalline cellulose, sucrose and isomalt were prepared. The developed system consisted of two types of drug-layered pellets attaining different release patterns: delayed-release (enteric-coated) and extended-release. Dissolution characteristics were examined using both compendial and biorelevant methods, which reflected fed and fasting conditions. The results were collated with an equivalent commercial product but prepared with the direct pelletization technique.